Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123456789>>>
422 Items
Title  Creator  Group name  Publishing year 
[Therapeutic advances in HER2+ breast cancer] Alexandre and Jacot EquipeCTCS 2023-04
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hurvitz et al. EquipeCTCS 2023-01-14
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database Mailliez et al. EquipeCTCS 2023-03-01
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeCTCS 2023-03-15
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program Le Du et al. EquipeCTCS 2023-10-03
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients Griguolo et al. EquipeCTCS 2023-09-15
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases Bottosso et al. EquipeCTCS 2023-03
Port placement strategies and management of the robotic system during total colectomy or total coloproctectomy for cancer - A video vignette Bourla et al. EquipeCTCS 2023-08
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Glaviano et al. EquipeCTCS 2023-08-18
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial Bidard et al. EquipeCTCS 2023-11-06
Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet? Quesada et al. EquipeCTCS 2023-07-10
NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells Campos-Mora et al. EquipeCTCS 2023
Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery Houvenaeghel et al. EquipeCTCS 2023-09-14
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers Hutchinson et al. EquipeCTCS 2023-04-26
Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer Sinoquet et al. EquipeCTCS 2023-01-04
Learning curve for robotic-assisted total mesorectal excision: a multicentre, prospective study Arquillière et al. EquipeCTCS 2023-09
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases Lazaratos et al. EquipeCTCS 2023-06
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study Fabbro et al. EquipeCTCS 2023-01
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy Garcia-Prada et al. EquipeCTCS 2023-10-19
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Tarantino et al. EquipeCTCS 2023-08
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes Chen et al. EquipeCTCS 2023-10
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation Frenel et al. EquipeCTCS 2023-06
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse Brouillard-Saby et al. EquipeCTCS 2023-04-03
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer Vendrell et al. EquipeCTCS 2023-09-16
123456789>>>
422 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés